Adaptimmune Therapeutics (ADAP) Q2 2024 earnings summary

Executive summary

• Achieved FDA approval and U.S. launch of Tecelra, the first engineered cell therapy for solid tumors and first new synovial sarcoma treatment in over a decade, now available for eligible patients.

• Launch activities began immediately post-approval, with commercial, medical, manufacturing, and supply teams fully operational; AdaptimmuneAssist patient support program is active, and 5 authorized treatment centers (ATCs) are available, with plans to expand to 6-10 during launch and up to 30 over time.

• Entered a major collaboration with Galapagos NV, securing $100M in upfront and R&D funding, with potential for further milestone and royalty payments.

• Terminated the Genentech collaboration, resulting in significant one-time revenue recognition and strategic refocus.

• Tecelra demonstrated a 43% overall response rate and 4.5% complete response rate in pivotal trials, with 39% of responders maintaining response for 12+ months.

Financial highlights

• Revenue for Q2 2024 was $128.2M, up from $5.1M in Q2 2023, driven by Genentech contract termination and Galapagos upfront payments.

• Net profit for Q2 2024 was $69.5M ($0.05/share), compared to a net loss of $21.4M in Q2 2023.

• Cash and cash equivalents at June 30, 2024, were $211.8M, with total liquidity of $214.8M, up from $144M at Q1.

• First half 2024 total expenditure was approximately $114M, including launch preparation and commercial team hiring.

• R&D expenses rose to $40.4M in Q2 2024 from $30.0M in Q2 2023; G&A expenses decreased to $19.1M from $20.1M year-over-year.

Outlook and guidance

• Focused on successful U.S. launch and commercialization of Tecelra, with plans to onboard 6-10 treatment centers in the coming weeks and up to 30 in two years.

• Peak U.S. sales estimate for the sarcoma franchise is $400M, with a 40%/60% split between Tecelra and lete-cel.

• Lete-cel regulatory submission planned for 2025, with commercial launch targeted for 2026 and full IGNYTE-ESO trial results expected by year-end 2024.

• Ongoing development of uza-cel in collaboration with Galapagos and continued investment in preclinical PRAME and CD70 programs.

• No further cash runway guidance will be provided due to near-term revenue estimation complexities; focus will shift to high-level cost guidance and launch metrics.